BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
월요일, 9월 21

Pacific Biosciences of California Inc

PACBNASDAQ
Trade with Public
Trade with Public
$1.37
-0.01-0.72%
가까이에: Sep 17, 5:00 PM EST
$1.37
-0.01-0.72%
프리마켓: 4:04 AM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Pacific Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pacific Biosciences (PACB).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

6Buy
5Hold
1Sell
Consensus RatingNeutral# Analysts12Avg. Consensus PT$2Upside to Avg. PT+67.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026UBSDoug SchenkelAssumesNeutral$2→$1
May 11, 2026BarclaysLuke SergottPT RaiseUnderweight$1→$2
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35

UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.
Benzinga Newsdesk

PRO
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.
Benzinga Newsdesk

PRO
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.
Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and raises the price target from $1.5 to $2.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $1.5 to $2.
Benzinga Newsdesk

PRO
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2

Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price target from $1.8 to $2.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved